• Corpus ID: 27908069

1 : Imaging the Alzheimer Brain : The Pathology and Pathophysiological Bases of Alzheimer ’ s Disease : Implications for Advancing Diagnostic Imaging

  title={1 : Imaging the Alzheimer Brain : The Pathology and Pathophysiological Bases of Alzheimer ’ s Disease : Implications for Advancing Diagnostic Imaging},
  author={J. Wesson Ashford and Ahmad Waleed Salehi and Ansgar J. Furst and Peter J Bayley and Giovanni Battista Frisoni and Clifford R. Jack and Osama Sabri and Maheen M. Adamson and Kerry L. Coburn and John M. Olichney and Norbert Schuff and Daniel Spielman and Steven D. Edland and Sandra E. Black and Allyson Rosen and David Kennedy and Michael W Weiner and George Perry},
This supplement to the Journal of Alzheimer’s Disease contains more than half of the chapters from The Handbook of Imaging the Alzheimer Brain, which was first presented at the International Conference on Alzheimer’s Disease in Paris, in July, 2011. While the Handbook contains 27 chapters that are modified articles from 2009, 2010, and 2011 issues of the Journal of Alzheimer’s Disease, this supplement contains the 31 new chapters of that book and an introductory article drawn from the… 

Figures and Tables from this paper


Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease
It is concluded that the combined use of conventional imaging, that is MRI or FDG‐PET, with selected CSF biomarkers incrementally contributes to the early and specific diagnosis of AD.
The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease
Criteria for the symptomatic predementia phase of Alzheimer’s disease (AD), referred to in this article as mild cognitive impairment due to AD, has four levels of certainty, depending on the presence and nature of the biomarker findings.
Diffusion tensor imaging of the hippocampus in MCI and early Alzheimer's disease.
Existing evidence indicates that DTI-derived mean diffusivity of the anterior hippocampus is more predictive than ordinary volumetric indices of the degree of episodic memory impairment in patients with early AD, thereby potentially qualifying this measure as a candidate marker for monitoring progression of AD.
Effects of hypoperfusion in Alzheimer's disease.
Hypoperfusion in AD is associated with both structural and functional changes in the brain and offers a promising putative biomarker that could potentially identify AD in its pre-clinical state and be used to explore treatments to prevent, or at least slow, the progression of the disease.
Neuroimaging through the course of Alzheimer's disease.
This review uses an image-indexed framework for the full course of Alzheimer's disease to provide a perspective on recent neuroimaging findings in the literature, and focuses on the AD pre-states and transition from mild cognitive impairment to mild AD.
Familial risk for Alzheimer's disease alters fMRI activation patterns.
It is demonstrated that asymptomatic individuals, at genetic risk for development of late-onset Alzheimer's disease by virtue of familial clustering, show functional activation patterns distinct from those without such risk more than a decade before their parent's onset age.
Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory
One possibility is that lifetime cerebral metabolism associated with regionally specific default activity predisposes cortical regions to AD-related changes, including amyloid deposition, metabolic disruption, and atrophy, which may be part of a network with the medial temporal lobe whose disruption contributes to memory impairment.
An MRI brain atrophy and lesion index to assess the progression of structural changes in Alzheimer's disease, mild cognitive impairment, and normal aging: a follow-up study.
The BALI rating quantified the progression of brain deficits over two years, which is associated with cognitive decline, and may be used to help summarize AD-associated structural variations.